Fuente: FierceBiotech Kyverna Therapeutics looks all the more likely to win the first FDA approval for a CAR-T therapy in an autoimmune disease after a registrational trial showed “highly statistically significant” benefits for the company’s CD19 agent on its primary endpoint and all secondary endpoints, according to the company.